Piramal Pharma Ltd
Piramal Pharma Ltd Share Price Today: Live Updates & Key Insights
Get insights on Piramal Pharma Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Piramal Pharma Ltd Share Price Chart
PPLPHARMA at 10 Jul 2026 06:27 PM Pharmaceuticals
177.16 +5.17(+3.01%)
Lowest Today 171.72
Highest Today 177.91
Today's Open 172.90
Prev. Close 171.99
52 Week High 240.95
52 Week Low 132.30
Piramal Pharma Ltd Fundamentals
Traded Volume: 53,45,065
Market Cap(Cr): 23,586.16
Avg Traded Price 176.21
1 Year return -12.06%
Upper Circuit 177.9
Lower Circuit 171.7
P/E TTM -72.00
P/B Ratio 2.797
Traded Value(Cr) 9469.32
EPS TTM -2.448
Book value/Share 61.500
Dividend Yield 1Y 0.08%
Piramal Pharma Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Piramal Pharma Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Piramal Pharma Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W +5.27%
1M +4.91%
3M +23.93%
1Y -12.06%
YTD +1.24%
Piramal Pharma Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Piramal Pharma Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 78.60L
Day Before Yesterday 69.38L
1W Avg 1.27Cr
1M Avg 1.13Cr
3M Avg 79.61L
Piramal Pharma Ltd Technical Details
Piramal Pharma Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 173
Support 2 169
Support 3 167
Pivot Point : 176
Resistance 1 179
Resistance 2 182
Resistance 3 186
Piramal Pharma Ltd Corporate Actions
Piramal Pharma Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Piramal Pharma Ltd’s capital allocation strategies.
All
Ex-Date 16-Jul-2025 Type D Description 0.14/share@1.40% Record Date 16-Jul-2025 Ratio 1.40
Ex-Date 12-Jul-2024 Type D Description 0.11/share@1.10% Record Date 12-Jul-2024 Ratio 1.10
Ex-Date 02-Aug-2023 Type R Description /share@5:46% Record Date 02-Aug-2023 Ratio 5:46
Dividends
Announcement Date 16-Jul-2025 Ex Dividend Date 16-Jul-2025 Dividend(%) 1
Announcement Date 12-Jul-2024 Ex Dividend Date 12-Jul-2024 Dividend(%) 1
Bonus
No Bonus has been declared by PPLPHARMA
Splits
No Split has been declared by PPLPHARMA
Others
Ex-Rights Date 02-Aug-2023 Premium(Rs.) 71.00 Ratio 5:46
Piramal Pharma Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Piramal Pharma Ltd with leading peers in the pharmaceuticals & biotechnology sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Piramal Pharma Ltd's relative performance and valuation against major competitors.
Stock Name Sai Life Sciences Ltd ₹1265.00 (+2.48%) M. Cap (Cr) 268.54 1 Yr Return (%) +61.90% P/E (TTM) 76.97 PB Ratio 10.81
Stock Name Neuland Laboratories Ltd ₹19506.00 (-0.18%) M. Cap (Cr) 250.26 1 Yr Return (%) +62.98% P/E (TTM) 68.75 PB Ratio 13.35
Stock Name Rubicon Research Ltd ₹1431.40 (+1.72%) M. Cap (Cr) 236.73 1 Yr Return (%) NaN% P/E (TTM) 95.94 PB Ratio 18.37
Stock Name Piramal Pharma Ltd ₹177.16 (+3.01%) M. Cap (Cr) 235.86 1 Yr Return (%) -12.06% P/E (TTM) -72.37 PB Ratio 2.89
Stock Name Granules India Ltd ₹889.85 (+0.88%) M. Cap (Cr) 220.50 1 Yr Return (%) +85.56% P/E (TTM) 37.06 PB Ratio 4.34
Stock Name Pfizer Ltd ₹4731.40 (+3.08%) M. Cap (Cr) 216.45 1 Yr Return (%) -16.54% P/E (TTM) 29.96 PB Ratio 5.15
Stock Name Astrazeneca Pharma India Ltd ₹8117.50 (+0.04%) M. Cap (Cr) 202.94 1 Yr Return (%) -12.61% P/E (TTM) 108.22 PB Ratio 23.25
Piramal Pharma Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Piramal Pharma Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2026 1328.12 Mar 2025 548.77 Mar 2024 358.29 Mar 2023 71.52 Mar 2022 255.20
PARTICULARS Investing Activities Mar 2026 -317.83 Mar 2025 -549.98 Mar 2024 -635.52 Mar 2023 -435.05 Mar 2022 -1223.02
PARTICULARS Financing Activities Mar 2026 -615.13 Mar 2025 -61.74 Mar 2024 451.38 Mar 2023 290.12 Mar 2022 905.74
PARTICULARS Net Cash Flow Mar 2026 395.16 Mar 2025 -64.93 Mar 2024 174.52 Mar 2023 -73.41 Mar 2022 -62.08
Piramal Pharma Ltd Shareholding Pattern
This shows the ownership breakdown of Piramal Pharma Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 34.86%
Public 19.01%
Other Institutions 1.49%
FII 30.17%
Mutual Funds 14.12%
About Piramal Pharma Ltd
Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company with the ROC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network. It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.Apart from this, the Company offers differentiated capabilities in niches areas such as highly potent APIs, antibody drug conjugates, potent sterile injectables, hormonal oral solid dosage forms and biologics and vaccines. The global distribution network gives it access to offer services and products to customers including large global pharma companies, biotech companies, hospitals and institutions.In June 2020, the Company acquired pharmaceutical business from Piramal Enterprises Limited (PEL).In October 2020, the Company received growth equity investment from the Carlyle Group. In It acquired 100% stake in Convergence Chemicals Private Limited (CCPL). It announced expansion for antibody drug conjugates at its Grangemouth (UK) facility and expansion of drug substance capabilities at its Riverview facility (USA).In 2021, it acquired Hemmo Pharmaceuticals Private Limited (HPPL), into the development and manufacturing of peptide APIs. On 7th October 2021, the Composite Scheme of Arrangement, which was entered into between the Company, Piramal Enterprises Limited, Convergence Chemicals Private Limited (CCPL), Hemmo Pharmaceuticals Private Limited (HPPL), PHL Fininvest Private Limited (PFPL) and their respective shareholders and creditors for demerger of Pharma Business from Piramal Enterprises Limited (PEL) to Company, amalgamation of CCPL and HPPL (both being wholly owned subsidiaries of the Company) into Company; and the amalgamation of PFPL (a wholly owned subsidiary of PEL) into PEL became effective from August 18, 2022.In consideration for the demerger, the equity shareholders of PEL as on the demerger record date received 4 equity shares of face and paid-up value of Rs 10 each of the Company for every 1 equity share of face and paid-up value of Rs 2 each held in PEL. i.e. 4:1. Accordingly, the Company was listed on the Stock Exchanges, BSE Limited (BSE) and National Stock Exchange of India Limited 'NSE) on October 19, 2022. In 2022, the Company acquired minority stake in Yapan Bio Private Limited, an India-Based CDMO providing expertise in biologics and vaccines. It launched 26 New products and 37 new SKUs during FY 2023.In FY24, Company launched 27 new products and 24 new SKUs ; launched 21 new products and 31 new SKUs in FY 2025. The Company commenced manufacturing lines at Digwal to supplement Sevoflurane manufacturing capacity at Bethlehem (US) in FY 2025.The Company expanded capacity at Dahej and commissioned new Sevoflurane production lines at Digwal in FY26. It acquired Kenalog from Bristol Myers Squibb during 2026.
Chairperson
Nandini Piramal
Registered office Ananta Bldg Piramal Corporate, Park LBS Marg Kurla west, Mumbai, Maharashtra, 400070
FAX :
Background
Incorporation Year 2020
Face Value ₹10.00
Market Lot 1
FAQs on Piramal Pharma Ltd
How to buy Piramal Pharma Ltd shares?
To buy Piramal Pharma Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the market cap of Piramal Pharma Ltd?
The company has a market capitalization of ₹23,586.16.
What is the PE & PB ratio of Piramal Pharma Ltd?
PE is -72 and PB is 2.797.
What is the Piramal Pharma Ltd dividend for 2025–26?
For the 2025–26 financial year, Piramal Pharma Ltd declared a final dividend of 0.08% per share.